Nasdaq auph.

Aurinia Pharmaceuticals Inc. NASDAQ: AUPH gapped up in heavy volume on the first trading day of the year and hasn’t looked back since. The Canadian biotech company launched LUPKYNIS two years ago as the first FDA-approved oral treatment for adults with active lupus nephritis (LN). This autoimmune disease affects more than …

Nasdaq auph. Things To Know About Nasdaq auph.

About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.Nov 22, 2021 · Aurinia Pharmaceuticals ( NASDAQ: AUPH) has been on a roll this year since their second quarter earnings in August. The stock jumped from $10 to over $30, buoyed by strong uptake of voclosporin ... Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results Business Wire - Thu May 4, 5:00AM CDT. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for first quarter ended March 31, 2023. Amounts are expressed in U.S. dollars. 9.28.What happened. Shares of the autoimmune specialist Aurinia Pharmaceuticals ( AUPH 2.09%) rose by as much as 13.2% in early morning trading Friday. The biotech's shares cooled off after their hot ...

Nasdaq provides company’s , which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC requires all publicly ...Back to AUPH Overview. Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or ...Aurinia AUPH announced that it has acquired two new pipeline candidates, which will target rare autoimmune and kidney-related diseases. Both the candidates, renamed as AUR200 and AUR300 following ...

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for third ...

October 30, 2023 at 7:26 AM · 3 min read We feel now is a pretty good time to analyse Aurinia Pharmaceuticals Inc.'s ( NASDAQ:AUPH) business as it appears the company …H.C. Wainwright analyst Ed Arce maintained a Buy rating on Aurinia Pharmaceuticals (NASDAQ: AUPH) on Friday, setting a price target of $35, which is approximately 142.38% above the present share ...AUPH Earnings Date and Information. Aurinia Pharmaceuticals last issued its quarterly earnings data on November 2nd, 2023. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.08. The company had revenue of $54.52 million for the quarter, compared to the consensus estimate of $38 ...Losses were broad based as all sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Intra-Cellular Therapies Inc ...msn.com - August 8 at 2:56 PM. Jump Financial LLC Takes $366,000 Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) marketbeat.com - August 8 at 5:21 AM. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) to Post Q1 2024 Earnings of ($0.14) Per Share, Leerink Partnrs Forecasts. marketbeat.com - August 7 at 7:47 AM.

Shares of NASDAQ AUPH opened at $9.06 on Monday. The company has a current ratio of 5.77, a quick ratio of 5.33 and a debt-to-equity ratio of 0.18. Aurinia Pharmaceuticals Inc. has a twelve month low of $4.07 and a twelve month high of $12.43. The stock has a 50 day moving average of $7.93 and a two-hundred day moving average of $9.20.

Aurinia Pharmaceuticals Inc. (AUPH) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 9.06 +0.42 (+4.86%) At close: 04:00PM EST 8.94 -0.12 (-1.32%) After hours: 07:59PM EST 1d

The public float for AUPH is 130.54M, and at present, short sellers hold a 13.23% of that float. The average trading volume of AUPH on November 20, 2023 was 1.70M shares. AUPH) stock’s latest price update. Aurinia Pharmaceuticals Inc (NASDAQ: AUPH)’s stock price has increased by 3.08 compared to its previous closing price of 8.60.To wit, the Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) share price is 78% higher than it was a year ago, much better than the market return of around 12% (not including dividends) in the same ...View the latest Aurinia Pharmaceuticals Inc. (AUPH) stock price, news, historical charts, analyst ratings and financial information from WSJ.The fact that multiple Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. When ...VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the ...

Big Biotech Stocks to Buy Under $10 #4: Aurinia Pharmaceuticals (AUPH) Source: Aurinia. Share Price: $5.46. Lupus remains one of the least understood auto-immune diseases. With lupus, the body’s ...Dec 4, 2023 · Avid Bioservices Inc (NASDAQ:CDMO)’s Major holders. Insiders own 0.82% of the company shares, while shares held by institutions stand at 108.12% with a share float percentage of 109.02%. Investors are also buoyed by the number of investors in a company, with Avid Bioservices Inc having a total of 253 institutions that hold shares in the company. Aurinia Pharmaceuticals (NASDAQ:AUPH) recently announced they have reached a settlement with Sun Pharmaceuticals (OTCPK:SMPQY) to dismiss their claims and counterclaims against each other.Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20)(NASDAQ: AUPH) Aurinia Pharmaceuticals currently has 143,608,164 outstanding shares. With Aurinia Pharmaceuticals stock trading at $8.23 per share, the total value of Aurinia Pharmaceuticals stock (market capitalization) is $1.18B .Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2023 Earnings Call Transcript November 2, 2023 Aurinia Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.17.2 нояб. 2023 г. ... Aurinia Pharmaceuticals (AUPH) reported better-than-expected Q3 2023 financials on Thursday driven by its lupus nephritis therapy Lupkynis.

Earnings vs Market: AUPH is forecast to become profitable over the next 3 years, which is considered above average market growth. High Growth Earnings: AUPH …Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Playstudios, Twitter, Aurinia, and Stronghold and Encourages Investors to Contact the Firm

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that leading independent proxy advisor Institutional Shareholder Services (“ISS”) has recommended that Aurinia shareholders vote FOR the re-election of all eight incumbent directors to the Board of Directors (the “Board”) at the Company’s 2023 …Get the latest Aurinia Pharmaceuticals Inc (AUPH) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Sep 18, 2023 · NASDAQ: AUPH Aurinia Pharmaceuticals. Market Cap. $1B. Today's Change (1.44%) $0.13. ... (AUPH 1.44%), a company focused on developing treatments for autoimmune diseases, saw its share price fall ... It has been quite some time since we last took a look at Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH). This small biopharma has been somewhat of a roller coaster ride for its shareholders in recent ...Cramer would be careful about Aurinia Pharmaceuticals Ord Shs (NASDAQ:AUPH). Sorrento Therapeutics Inc (NASDAQ:SRNE) is overvalued, said Cramer. He is a seller.Total cost of sales and operating expenses for the quarter ended September 30, 2023 was $70.8 million and $65.3 million for the quarter ended September 30, 2022. Total cost of sales and operating ...NASDAQ:AUPH. Press Releases. May 17, 2023. Aurinia Announces 2023 Annual General Meeting Results May 09, 2023. Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS ...Nov 29, 2023 · AUPH | Complete Aurinia Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Nasdaq provides company’s , which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC requires all publicly ...

NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...

May 22, 2023 · Last month, AUPH's second largest shareholder, MKT Capital, which holds 4.2% of the stock, wrote a scathing letter to shareholders, calling to withdraw support for CEO Peter Greenleaf, board ...

Sep 15, 2023 · 8.82%. 141,687,578. 12,497,875. 1,990,667. 6.28. Data brought to you by Benzinga APIs. Looking for the most shorted stocks? Short interest for Aurinia Pharmaceuticals gives investors a sense of ... Gainers iSpecimen Inc. (NASDAQ:ISPC) shares climbed 126.5% to $11.12 after the company announced it has been contracted to support new advanced ...Aurinia Pharmaceuticals (NASDAQ:AUPH) has been subject to buyout speculations for well over a year now. It was as early as May 2021, when The Times mentioned AstraZeneca ( AZN ) or GSK ( GSK ) are ...2 нояб. 2023 г. ... Aurinia Pharmaceuticals (AUPH) reported better-than-expected Q3 2023 financials on Thursday driven by its lupus nephritis therapy Lupkynis.The new research reports from Fundamental Markets, available for free download at the links above, examine B Communications Ltd. (NASDAQ:BCOM), Student Transportation Inc (NASDAQ:STB), Aurinia ...Market Capitalization. $1.24 billion. P/E Ratio. N/A. Dividend Yield. N/A. Price Target. $14.00. Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Options Chain Ownership SEC Filings Short Interest Social Media.Aurinia Pharmaceuticals AUPH shares ended the last trading session 5.7% higher at $9.68. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...Nov 29, 2023 · AUPH | Complete Aurinia Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Aurinia Pharmaceuticals (NASDAQ:AUPH) could see prices in the high $20s to low $30s per share in a takeout at premium multiples, according to RBC, after the company announced Thursday it was ...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ranks 6th in our list of the best stocks with exponential growth according to hedge funds. In September Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ...EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the ...AUPH Latest After Hours Trades. Select time range to see more trades: Last 100 Trades. After Hours Time (ET) After Hours Price. After Hours Share Volume. 19:59:23. $9.37. 100. Within the last quarter, Aurinia Pharmaceuticals (NASDAQ:AUPH) has observed the following analyst ratings: Menu icon A vertical stack of three evenly spaced horizontal lines.Instagram:https://instagram. swing trading classesmetlife vs delta dental3 year treasury bond rateinsider stock buys EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the third ... mnauctioncommercial real estate short etf Aurinia Pharmaceuticals (AUPH) closed the last trading session at $9.80, gaining 0.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ... steel etf AUPH Latest After Hours Trades. Select time range to see more trades: Last 100 Trades. After Hours Time (ET) After Hours Price. After Hours Share Volume. 19:59:23. $9.37. 100. NASDAQ:AUPH. Press Releases. May 17, 2023. Aurinia Announces 2023 Annual General Meeting Results May 09, 2023. Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS ...